Form 8-K - Current report:
SEC Accession No. 0001193125-25-079090
Filing Date
2025-04-11
Accepted
2025-04-11 16:03:41
Documents
13
Period of Report
2025-04-07
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d912643d8k.htm   iXBRL 8-K 24851
  Complete submission text file 0001193125-25-079090.txt   147424

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vinc-20250407.xsd EX-101.SCH 2839
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20250407_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20250407_pre.xml EX-101.PRE 11251
15 EXTRACTED XBRL INSTANCE DOCUMENT d912643d8k_htm.xml XML 3631
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 25831526
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)